Live
- A Guide to Temperature and Humidity Standards in Data Center Server Rooms
- Gadwal collector briefs on details of voters
- Jupally Krishna Rao takes part in Alampur rallu
- Bharath Prasad files 3rd Nomination
- Baisakh Month: A Time of Auspicious Beginnings and Sacred Festivals
- Oust BJD govt for overall development, says Shah
- Unveiling the Hidden Gems: Surprising Health Benefits of Garlic Peels
- Overcoming Sleep Struggles: A Comprehensive Guide to a Restful Night
- RTC bus hit the auto
- MLA Kuchukula Rajesh Reddy participated in the Birappa festival
Aurobindo to build around 150 products in next 3 years
Aurobindo Pharma is focussing on building a diverse speciality portfolio of nearly 150 products with an addressable market size of 1182 billion in the next three financial years, the drug firm said in an investor presentation on Monday
Hyderabad: Aurobindo Pharma is focussing on building a diverse speciality portfolio of nearly 150 products with an addressable market size of $118.2 billion in the next three financial years, the drug firm said in an investor presentation on Monday.
The speciality portfolio will be in various therapeutic segments such as oncology and hormones, biologics, topicals, nasals, peptides, depot injection, inhalers, vaccines and transdermal patches totalling 147 products under development.
In a regulatory filing to BSE, the company said 79 products are under development in oncology and hormones, 22 are in topicals, 5 are in nasals, 14 are in peptides and 4 in depot injection segment.
The other products under development are 8 in transdermal patches, 8 in inhalers, 6 in biologics and one in vaccines, it added. While largest addressable market size is $45 billion for oncology and hormones segment, it is $35 billion for biologics and $12.2 billion for peptides segment, the presentation said.
The addressable market size is $7.5 billion for inhalers, $6.2 billion for vaccines, $5 billion for topicals, $3.6 billion for depot injection, $3.2 billion for transdermal patches and $0.5 billion for nasals, it added.
The revenue generation will start from first quarter of 2019-20 for oncology and hormones, from 2020-21 for topicals, from 2019-20/2020-21 for nasals, from 2020-21 for peptides and from 2021-22 for depot injections, it added.
The revenue generation will start from 2020-21 for transdermal patches, from 2021-22 for inhalers, from 2021-22 for biologics and from 2021-22 for vaccines, the presentation said. Commenting on the filing targets, Aurobindo said it plans to file all products over next 3 years in the oncology and hormones segment.
In topicals, it is looking to file all products over next 2-3 years. For nasals, the company plans to file all products by 2019-20. While in the peptides segment the company plans to file 5 more DMFs over next 18 months, it plans to file all products by 2021-22 for the depot injection segment.
The company plans to file all products over next 3 years in transdermal patches. It is planning to file all products over next 3 years in inhalers, to file first set of products by 2021-22 in biologics and vaccine by 2020-21, Aurobindo Pharma said.
